中国药业2025，Vol.34Issue(11)：119-122,4.DOI:10.3969/j.issn.1006-4931.2025.11.025
1例替雷利珠单抗致免疫性结膜炎药学监护
Pharmaceutical Care of One Case of Immune Conjunctivitis Induced by Tislelizumab
摘要
Abstract
Objective To provide a reference for the clinical safe use of tislelizumab.Methods A retrospective analysis was conducted on the clinical data,treatment process,and pharmaceutical care of a patient with immune-mediated conjunctivitis induced by tislelizumab admitted to the hospital.The diagnosis and treatment experience were summarized.Results The patient was diagnosed with colorectal adenocarcinoma with liver,lung,and peritoneal metastases and was treated with intravenous infusion of 200 mg of tislelizumab every 3 weeks,with an interval of 1 week,as one treatment cycle.After three cycles of treatment,the patient experienced discomfort in the eyelids,conjunctival congestion,unclear vision,and secretion attachment.The patient was considered to have immune conjunctivitis and received systemic corticosteroid treatment and enhanced nutritional support upon admission to the hospital.During the treatment period,the clinical pharmacist strengthened pharmaceutical care,assisted the physician in formulating the treatment plan,the physician adopted the advice of clinical pharmacists and adjusted the treatment plan and medication dosage in a timely manner,and the patient's conjunctivitis symptoms gradually improved.After evaluating the risks and benefits of immune checkpoint inhibitors,the patient's anti-tumor treatment drug was changed from tislelizumab to targeted therapy with fruquintinib alone,and no conjunctivitis occurred again.Conclusion When tislelizumab used in the clinic,the patient's immune-related adverse reactions(irAEs)should be closely monitored,and the clinical pharmacist should regularly carry out pharmaceutical care to assist the physician in identifying and evaluating irAEs in a timely manner,and formulate a treatment plan based on the patient's condition to ensure the medication safety and effectiveness of patients.关键词
替雷利珠单抗/免疫性结膜炎/药品不良反应/药学监护Key words
tislelizumab/immune conjunctivitis/adverse drug reaction/pharmaceutical care分类
医药卫生引用本文复制引用
黄玉,陈辉玲,李家伟,张燕,肖溢..1例替雷利珠单抗致免疫性结膜炎药学监护[J].中国药业,2025,34(11):119-122,4.基金项目
北京医药卫生经济研究会科研资助项目[BJHE2023-PRP-010]. （）
